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Introduction: The majority of kidneys used for transplantation are retrieved from brain-
dead organ donors. In brain death, the irreversible loss of brain functions results in
hemodynamic instability, hormonal changes and immunological activation. Recently,
brain death has been shown to cause activation of the complement system, which
is adversely associated with renal allograft outcome in recipients. Modulation of the
complement system in the brain-dead donor might be a promising strategy to improve
organ quality before transplantation. This study investigated the effect of an inhibitory
antibody against complement factor B on brain death-induced renal inflammation
and injury.
Method: Brain death was induced in male Fischer rats by inflating a balloon catheter
in the epidural space. Anti-factor B (anti-FB) or saline was administered intravenously
20min before the induction of brain death (n = 8/group). Sham-operated rats served as
controls (n = 4). After 4 h of brain death, renal function, renal injury, and inflammation
were assessed.
Results: Pretreatment with anti-FB resulted in significantly less systemic and local
complement activation than in saline-treated rats after brain death. Moreover, anti-FB
treatment preserved renal function, reflected by significantly reduced serum creatinine
levels compared to saline-treated rats after 4 h of brain death. Furthermore, anti-FB
significantly attenuated histological injury, as seen by reduced tubular injury scores, lower
renal gene expression levels (>75%) and renal deposition of kidney injury marker-1. In
addition, anti-FB treatment significantly prevented renal macrophage influx and reduced
systemic IL-6 levels compared to saline-treated rats after brain death. Lastly, renal
gene expression of IL-6, MCP-1, and VCAM-1 were significantly reduced in rats treated
with anti-FB.
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Conclusion: This study shows that donor pretreatment with anti-FB preserved renal
function, reduced renal damage and inflammation prior to transplantation. Therefore,
inhibition of factor B in organ donors might be a promising strategy to reduce brain
death-induced renal injury and inflammation.
Keywords: factor B, complement, renal transplantation, brain death, donation
INTRODUCTION
Although the field of renal transplantation has made huge
progress over the last 50 years, one of the main challenges
remains the disparity between demand and supply of renal
allografts (1). Therefore, increasing efforts are made to
expand, but also to optimize the current donor pool. Kidneys
are retrieved from living donors, deceased after circulatory
death (DCD) donors, and deceased after brain death (DBD)
donors. Despite the increasing number of living donors, the
majority of kidneys are still retrieved from DBD donors
(1). However, brain death induces physiological disturbances
characterized by hemodynamic changes, metabolic disturbances,
and immunological derangements. Therefore, kidneys retrieved
from DBD donors give inferior results, reflected by a higher rate
of delayed graft function than their living counterparts (2).
An important denominator in brain death-induced renal
inflammation is activation of the complement system (3, 4).
The complement system can be activated by three different
pathways: the classical pathway (CP), the lectin pathway (LP),
and the alternative pathway (AP). Activation of each of these
three pathways results in the cleavage of complement component
C3 into C3a and C3b. Subsequently, activation of C3 leads to
the formation of the C5 convertases, which cleave C5 into C5a
and C5b. C5b is the initial protein for the formation of C5b-
9, also known as the membrane attack complex (MAC). The
MAC induces the formation of pores in the cell membrane, which
results in cell lysis. Besides, C5b-9 induces tissue injury via intra-
cellular pro-inflammatory signaling pathways (5). In addition,
the anaphylatoxins C3a and C5a are produced, which provoke
influx and activation of inflammatory cells (6, 7).
Early studies already have demonstrated the presence of
complement C3 in kidneys from DBD rats (8). C3 deposition
was seen on endothelial cells and in the glomeruli of DBD-
derived kidneys, while no C3 deposition was observed in renal
biopsies from living donors. In line with these results, C3d
deposition was detected in renal biopsies from human DBD
donors before reperfusion (9, 10), which suggest that C3d was
deposited as a direct result of brain death itself. Complement
C3 activation results in the production of the downstream
activation products C5a and C5b-9, which are both systemically
Abbreviations: AEC, 3-amino-9-ethylcarbazole; Anti-FB, anti-factor B; AP,
alternative pathway; ATN, acute tubular necrosis; CP, classical pathway; DAB,
3,3-diaminobenzidine; DBD, donation after brain death; DCD, donation after
circulatory death; HAES, hydroxyethyl starch solution; KIM-1, kidney injury
molecule-1; LP, lectin pathway; MAC, membrane attack complex; MAP, mean
arterial pressure; PBS, phosphate buffered saline; PEG, polyethylene glycol; TMB,
3,3′,5,5′-tetramethylbenzidine.
and locally upregulated in the DBD donor (11, 12). These
studies demonstrate that the complement system is activated in
DBD donors. Therefore, inhibition of the complement system
might be an attractive strategy to attenuate brain death-induced
renal injury (13).
A potential target for intervention in the DBD donor might
be complement factor B. Factor B is one of the key components
required for activation of the complement AP (9, 14). Bb, an
active fragment of factor B, is significantly elevated in plasma
from DBD donors compared to living donors (11). These plasma
levels of Bb are positively correlated with systemic C5b-9 levels
in DBD donors. High systemic C5b-9 levels in DBD donors
are associated with a higher incidence of acute rejection in
the recipient (11). In addition, local renal expression of factor
B was significantly increased in kidneys from DBD donors
compared to kidneys from living donors at baseline (15). These
studies demonstrate that factor B is both systemically and locally
upregulated in kidneys from DBD donors. Therefore, inhibition
of factor B could be critical to protect against brain death-induced
renal injury. To our knowledge, no studies have investigated
whether inhibition of factor B is therapeutically effective in
DBD donors.
Our study aimed to investigate whether inhibition of
factor B can attenuate brain death-induced renal injury and
inflammation. To do so, we pretreated rats with a monoclonal
antibody against factor B (anti-FB) and subsequently subjected
rats to 4 h of brain death. We found that pretreatment with anti-
FB significantly improved renal function, reduced renal damage,
and inflammation in brain-dead rats prior to transplantation.
MATERIALS AND METHODS
Experimental Outline
In this study, 22 rats (two rats were excluded because of technical
failures and replaced) were randomly divided into the following
groups (Figure 1):
Brain death with saline (control group) (n= 8)
Brain death with anti-factor B (anti-FB) (n= 8)
Sham-operation with saline (n= 4).
Rats
Adult male Fischer F344/NHsd rats (Envigo, Dublin, VA, USA)
between 250 and 300 grams were used. Rats received food
and water ad libitum. All experiments were performed at the
local animal facility of the University Medical Center Groningen
according to the Experiments on Animal Act (1996) issued by the
Ministry of Public Health,Welfare and Sports of the Netherlands.
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FIGURE 1 | Schematic overview of the experimental set-up. To induce brain death, a catheter was placed in the epidural space through a frontal-lateral borehole in
the skull and inflated slowly over 30min. (A) Saline or (B) anti-factor B (anti-FB) was administered via the femoral vein 20min before the induction of brain death. After
4 h of brain death, rats were sacrificed and blood, urine and kidneys were collected. In (C) sham-operated rats, a hole was drilled in the skull without insertion of the
balloon catheter and rats were ventilated for 30min under anesthesia before sacrifice.
†
Termination. Anti-FB, anti-factor B.
TABLE 1 | Overview of the fluids administered, when mean arterial pressure
dropped below 80 mmHg, in rats during the 4 h brain death period.





Median IQR Median IQR
HAES (ml) 1 0–1.5 0.8 0–1.5 0.479
Noradrenaline (ml) 0.295 0–1.9 0.25 0–2.88 0.989
MAP (mmHg) 100 90–110 103 79–115 0.787
IQR, interquartile range; HAES, hydroxyethyl starch solution; MAP, mean arterial pressure.
Brain Death Procedure
To test whether inhibition of the complement AP protects against
brain death-induced renal injury, we treated brain-dead rats
with a mouse anti-human monoclonal antibody against factor
B (FB28.4.2; IgG2b). FB28.4.2 (anti-FB) is produced in the
laboratory of prof. Dr. Santiago Rodriquez de Cordoba at the
Centro de Investigaciones Biológicas, Madrid, Spain. Anti-FB is
an inhibitory antibody, which targets an evolutionary-conserved
epitope in the Ba fragment of factor B. Anti-FB efficiently inhibits
the formation of the AP C3 proconvertase in humans, rats
and other species by blocking the interaction between the Ba
domain of factor B and C3b (16). Twenty minutes before the
start of brain death induction, 8mg of purified anti-FB in a total
volume of 750 µl, was administered via the femoral vein. Saline,
used in the control group and sham-operated group, was also
administered via the femoral vein at the same time and in the
same volume as anti-FB. Brain death was induced as described
previously (17). Briefly, rats were anesthetized, intubated and
ventilated. Temperature and mean arterial pressure (MAP) were
continuously monitored and regulated. A 4F Fogarty balloon
catheter (Edwards Lifesciences LLC, Irvine, USA) was placed in
the epidural space through a frontal-lateral borehole in the skull
and inflated slowly. Brain death induction was completed after
30min, and the apnoea test confirmed brain death. Subsequently,
anesthesia was stopped and the ventilator was switched to a
mix of 50% O2 and 50% medical air. A MAP above 80 mmHg
was considered to be normotensive. When MAP dropped below
80 mmHg, 0.1 kg/L hydroxyethyl starch solution (HAES-steril
10%, Fresenius Kabi, Bad Homburg, Germany) and, if necessary,
0.01 mg/ml norepinephrine were administered. A maximum of
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800 µl of fluid was administered during 4 h of brain death.
Fluid administration was comparable in all groups (Table 1).
Blood, urine and kidneys were harvested after 4 h of brain death.
Kidneys were embedded in paraffin or snap-frozen in liquid
nitrogen and together with the serum and urine stored at−80◦C.
Sham-operated rats underwent the same surgical procedure, but
without the insertion of the balloon catheter, and only received
saline. Sham-operated rats were ventilated for 30min under
anesthesia with a mixture of 2.5% isoflurane and 100% O2. After
30min, sham-operated rats were sacrificed.
Renal Function
To investigate renal function, serum creatinine levels were
measured at the time of sacrifice, using a RocheModular P system
(Roche, Basel, Switzerland).
Renal Morphology
Paraffin sections (4µm) were stained with Periodic Acid-Schiff
stain. Histological injury, reflected by acute tubules necrosis
(ATN) was determined semi-quantitatively by two observers
using the following scoring system: 0= no ATN; 1= 0–10%; 2=
10–25%; 3= 25–50% and 4=≥50% ATN.
Immunohistochemistry
Immunohistochemical stainings for C3d, C5b-9, and neutrophils
(HIS48) were performed on frozen sections (4µm) fixed in
acetone. Immunohistochemistry for kidney injury molecule-1
(KIM-1) and macrophages (ED-1) were performed on formalin-
fixed, paraffin-embedded sections. Paraffin sections (4 µm)
were deparaffinized and rehydrated. 0.1M Tris/HCl (pH 9)
was used as an antigen retrieval buffer. All sections were
blocked with hydrogen peroxidase for 30min and incubated with
the primary antibody for 1 h at room temperature (Table 2).
After washing with phosphate buffered saline (PBS), the slides
were incubated with the appropriate horseradish peroxidase-
conjugated secondary and tertiary antibodies (Dako, Carpinteria,
USA) in 1% BSA solution for 30min. The reaction was developed
by addition of 3-amino-9-ethylcarbazole (AEC; Dako) or 3,3-
diaminobenzidine (DAB; Merck, Darmstadt, Germany) and
0.03%H2O2. Sections were counterstained with hematoxylin and
embedded in Aquatex mounting agent (Merck).
For quantitative evaluation of HIS48 and ED-1 in the renal
cortex, 40 snapshots of the renal cortex were taken from
the representative sections using ImageJ Software (National
Institutes of Health). Cells positive for each marker were then
counted using Aperio ImageScope Analysis Software (objective
50x−200x) (Leica Biosystems, Vista, CA, USA). C3d, C5b-9, and
KIM-1 sections were scored semi-quantitatively by two observers
at a magnification of 20x. C3d and C5b-9 were scored by the
following scoring system: 0 = no staining; 1 = 0–25%; 2 =
25–50%; 3 = 50–75% and 4 = 75–100% staining in the renal
cortex. KIM-1 was scored by estimating the percentage of KIM-1
expression in the cortical tubules. KIM-1 was scored per field, as
described by van Timmeren et al. (18). In brief, 0 = no staining;
1/2= 0–12.5%; 1= 12.5–25%; 2= 25–50%; 3= 50–75% and 4=
75–100%.
IL-6 ELISA
Plasma protein levels of IL-6 were determined by a rat enzyme-
linked immunosorbent assay (R&D Systems; DY506, Abingdon,
Oxon, UK). All samples were analyzed in duplicate andmeasured
at an optical density of 450 nm.
C3d ELISA
Rat C3d ELISA was performed, as described previously, to
measure complement activation after 4 h of brain death (19).
In brief, rat C3d was captured with a monoclonal mouse anti-
C3 antibody (sc-28294, Santi Cruz, CA, USA). A rabbit anti-
human C3d was used as detection antibody (Dako) and goat anti-
rabbit-HRP (Dako) with 3,3′,5,5′-Tetramethylbenzidine (TMB)
K-Blue as substrate. Sample incubation and detection steps
were performed for 60min at 37◦C. Before C3d was measured,
all samples were polyethylene glycol (PEG) precipitated. PEG
precipitation is required since free C3d shares epitopes with
intact C3. All plasma samples were 1:1 diluted with 22% PEG
in 0.1M borate/EDTA buffer (pH 8.32). Samples were incubated
for 3 h on ice and subsequently centrifuged for 10min at 4000
rpm at 4◦C. Then, supernatants were collected and used for
C3d quantification. A standard curve was made using zymosan-
activated pooled rat plasma. The amount of C3d in the samples
was determined from the standard curve and expressed in
arbitrary units/ml. Samples were analyzed in duplicate and
measured at an OD of 450 nm (VICTOR-3, 1420 multilabel
counter, PerkinElmer, Waltham, US).
RNA Isolation
RT-qPCR was performed to investigate the renal gene expression
levels of pro-inflammatory cytokines after brain death. Total
RNAwas extracted from frozen kidneys using the TRIzol method
(Invitrogen, Waltham, US) and DNase Amplification Grade
(Merck), according to manufacturer’s instructions. Genomic
DNA contamination was verified by RT-qPCR using β-
actin primers, in which the addition of reverse transcriptase
was omitted.
cDNA Synthesis and qPCR
cDNA synthesis was performed by the addition of 0.5 µl
sterile water, 4 µl 5x first strand buffer (Invitrogen), 2 µl
DTT (Invitrogen), and 1 µl M-MLV Reverse Transcriptase
(Invitrogen) and primers (Table 3). The mixture was then
incubated for 50min at 37◦C. After that, the reverse transcriptase
was inactivated by incubating the mixture at 70◦C for 15min.
The Taqman Applied Biosystems 7900HT RT-qPCR system
(Biosystems, Carlsbad, USA) was used to amplify and detect PCR
products, using SYBR Green (Applied Biosystems, Foster City,
USA). Ct values were corrected for ß-actin and gene expression
values were expressed as 2−11CT (Ct: threshold cycle).
Statistical Analysis
Statistical analyses were performed with IBM SPSS Statistics
23 (IBM Corp, Armonk, NY, USA). The Kruskal-Wallis test
was performed for multiple group comparisons. The Mann-
Whitney U test was used to compare the differences between two
groups. Bonferroni correction was used to account for multiple
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TABLE 2 | Primary antibodies used for immunohistochemistry.
Antibody Sections Host and target species Supplier 2nd/3rd antibodies
C3d Frozen Rabbit polyclonal anti-human C3d A0063, Dako, Carpinteria, USA GαRbPO/RbαGPO
C5b-9 Frozen Mouse monoclonal anti-rat membrane attack complex Hycult, Uden, the Netherlands RbαMPO
ED-1 Paraffin Mouse monoclonal anti-rat macrophages/monocytes Abcam, Oxford, UK RbαMPO/GαRbPO
HIS48 Frozen Mouse monoclonal anti-rat granulocytes IQProducts, Groningen, the Netherlands RbαMPO/GαRbPO
KIM-1 Paraffin Mouse monoclonal anti-human KIM-1 AKG7 Biogen Inc, Cambridge, Massachusetts, USA RbαMPO/GαRbPO
G, goat; Rb, rabbit; M, mouse; PO, polyclonal; KIM-1, kidney injury molecule-1.
TABLE 3 | Gene-specific qPCR primers.





















β-actin, βeta-actin; BAX, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma protein
2; IL, Interleukin; KIM-1, kidney injury molecule-1; MCP-1, monocyte chemoattractant
protein-1; VCAM-1, vascular cell adhesion molecule-1.
comparisons. All statistical tests were 2-tailed and a p < 0.05
was considered significant. Non-parametric data are presented as
median ± interquartile range and parametric data are displayed
as mean± SD.
RESULTS
Treatment With Anti-factor B Prevents
Both Systemic and Local Complement
Activation in Rats Subjected to Brain Death
To investigate whether the complement system is activated in
our rat brain death model, we determined systemic and local
complement activation levels after 4 h of brain death. Systemic
C3d levels were significantly increased after the induction of
brain death (Figure 2A, p < 0.05) when compared to sham-
operated rats, which indicates that the complement system was
indeed activated upon brain death.
Next, we assessed whether treatment with anti-FB was able
to prevent systemic complement activation in rats. Pretreatment
with anti-FB prevented complement activation significantly,
shown by comparable C3d levels as found in sham-operated
rats (Figure 2A, p < 0.01). In addition, we determined whether
treatment with anti-FB led to less local complement activation.
There was no significant increase in C5b-9 deposition after 4 h
of brain death compared to sham-operated rats (Figure 2B).
However, renal C3d deposition was significantly increased in
brain-dead rats compared to sham-operated rats (Figure 2C, p
< 0.01). In addition, brain-dead rats pretreated with anti-FB
had significantly less renal C3d deposition than saline-treated
rats (Figures 2C–F, p < 0.05). Overall, anti-FB significantly
prevented both systemic and local complement activation on the
level of C3 after 4 h of brain death.
Anti-factor B Preserves Renal Function and
Attenuates Renal Injury After Brain Death
To determine whether treatment with anti-FB was able to
preserve renal function and protect against renal injury, we
measured serum creatinine levels, scored for histological injury
and investigated kidney injury molecule-1 (KIM-1) levels in the
kidney. First, plasma creatinine levels were significantly elevated
after brain death compared to sham-operated rats (Figure 3A, p
< 0.001). Pretreatment with anti-FB preserved renal function,
reflected by significantly lower serum creatinine levels than
saline-treated rats after brain death (Figure 3A, p < 0.01).
However, serum creatinine levels in anti-FB treated rats were
still significantly higher than in sham-operated rats. Second,
anti-FB treated rats had significant less renal injury than saline-
treated brain-dead rats, demonstrated by lower levels of renal
tubular necrosis (Figure 3B, p < 0.05). Third, mRNA expression
of KIM-1, a protein which is mainly expressed on damaged
renal epithelial cells (18), was significantly upregulated in brain-
dead rats compared to sham-operated rats. Pretreatment with
anti-FB resulted in significantly lower KIM-1 gene expression
levels, which indicates a reduction in renal tubular damage
(Figure 3C, p < 0.05). Lastly, we analyzed renal KIM-1
deposition by performing immunohistochemistry. Brain-dead
rats had significant more KIM-1 protein deposition in the
proximal renal tubules than sham-operated rats. After brain
death, KIM-1 staining was primarily seen in the corticomedullary
junction. Anti-FB treated rats had significantly less KIM-1
deposition than saline-treated rats (Figures 3D–G, p < 0.05).
Taken together, these results show that pretreatment with anti-FB
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FIGURE 2 | Systemic and local complement levels after 4 h of brain death. (A) Systemic C3d levels of brain-dead rats treated with saline or anti-factor B. Plasma C3d
levels were determined after 4 h of brain death. C3d was captured by using a monoclonal mouse anti-C3 antibody, detected with a rabbit anti-human C3d antibody
and goat anti-rabbit-HRP. (B) Renal C5b-9 deposition and (C) renal C3d deposition in frozen sections from (D) sham-operated rats, (E) saline-treated rats, and (F)
anti-factor B treated rats after 4 h of brain death. Data are shown as median ± IQR. Data were analyzed by Mann Whitney-U-test and Bonferroni post-hoc test,
asterisks above the bars denote significant differences between the brain-dead rats (*p < 0.05, **p < 0.01, and ***p < 0.001). The dashed line represents the mean of
the sham-operated rats. #Significant differences between the brain-dead rats vs. sham-operated rats (#p < 0.05, ##p < 0.01, and ###p < 0.001). Anti-FB,
anti-factor B.
preserved renal function and attenuated brain death-induced
renal injury.
Anti-factor B Reduces Systemic IL-6
Levels and Expression Levels of
Pro-inflammatory Genes in the Kidney
To assess whether complement inhibition with anti-FB influences
brain death-induced renal inflammation, we first determined
systemic IL-6 levels after 4 h of brain death. IL-6 plasma
levels were significantly higher in saline-treated brain-dead
rats than in sham-operated rats (Figure 4A, p < 0.001).
Pretreatment with anti-FB prevented the increase of systemic
IL-6 significantly compared to saline-treated rats after brain
death (Figure 4A, p < 0.05). Next, we determined renal mRNA
levels of multiple pro-inflammatory genes. After 4 h of brain
death, the pro-inflammatory cytokines IL-6, IL-18, and IL-1β,
adhesion molecules P-selectin and VCAM-1, chemokine MCP-1,
and apoptosis ratio BAX/Bcl-2 were all significantly upregulated
compared to sham-operated rats (Figures 4B–H). These data
demonstrate that our rat brain death model mimics the injury
seen in human brain-dead donors (20). Rats treated with anti-FB
showed significantly lower renal gene expression levels of pro-
inflammatory cytokine IL-6 (Figures 4B,C, p < 0.01). Besides,
renal gene expression levels of VCAM-1 and MCP-1 were
significantly lower in anti-FB treated rats than in saline-treated
rats upon brain death (Figures 4F,G, p < 0.01). Gene expression
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FIGURE 3 | Renal function and renal injury upon brain death with saline or anti-factor B. (A) Renal function reflected by plasma creatinine levels of brain-dead rats
treated with saline or anti-FB compared to sham-operated rats. Serum creatinine levels were measured at time of sacrifice, using a Roche Modular P system. (B)
Tubular damage was reflected as a percentage of acute tubular necrosis in the renal cortex using a semi-quantitative method. (C) Renal KIM-1 gene expression in
brain-dead and sham-operated rats treated with saline or anti-FB was determined by quantitative real-time PCR. The mRNA expression of KIM-1 relative to β-actin
was set at 1 in sham-operated rats, the other values, are calculated accordingly. (D) Renal KIM-1 deposition after 4h of brain death, KIM-1 was scored by estimating
the percentage of KIM-1 expression in the cortical tubules. (E) KIM-1 deposition in sham-operated rats, (F) in saline-treated rats, and (G) anti-FB treated rats. Data are
shown as median ± IQR. Data were analyzed by Mann Whitney-U-test and Bonferroni post-hoc test, asterisks above the bars denote significant differences between
the brain-dead rats (*p < 0.05, **p < 0.01, and ***p < 0.001). The dashed line represents the mean of the sham-operated rats. #Significant differences between the
brain-dead rats vs. sham-operated rats (#p < 0.05, ##p < 0.01, and ###p < 0.001). Anti-FB, anti-factor B.
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FIGURE 4 | Pro-inflammatory gene expression levels in the kidney after 4 h of brain death. (A) Systemic IL-6 levels of brain-dead rats treated with saline or anti-FB
compared to sham-operated rats after 4 h of brain death. A rat enzyme-linked immunosorbent assay determined plasma levels of IL-6. All samples were analyzed in
duplicate and measured at an OD of 450 nm. Pro-inflammatory gene expressions in the kidneys of brain-dead rats treated with saline or anti-factor B. mRNA
expressions of (B) IL-6, (C) IL-18, (D) IL-1β, (E) P-selectin, (F) VCAM-1, (G) MCP-1, and (H) BAX/Bcl-2 ratio. Data are shown as expression relative to β-actin as set
at 1 in sham-operated rats, the other values, are calculated accordingly. Data are shown as median ± IQR. Data were analyzed by Mann Whitney-U-test and
Bonferroni post-hoc test, asterisks above the bars denote significant differences between the brain-dead rats (*p < 0.05, **p < 0.01, and ***p < 0.001). The dashed
line represents the sham-operated rats. #Significant differences between the brain-dead rats vs. sham-operated rats (#p < 0.05, ##p < 0.01, and ###p < 0.001).
Anti-FB, anti-factor B.
Frontiers in Immunology | www.frontiersin.org 8 November 2019 | Volume 10 | Article 2528
Jager et al. Anti-factor B in Brain Death
FIGURE 5 | Infiltrated leukocytes in the kidney after brain death in saline or anti-factor B treated rats. Infiltrated leukocytes in kidneys of sham-operated and
brain-dead rats treated with saline or anti-factor B. (A) Renal neutrophil influx was scored in frozen sections from (B) sham-operated rats, (C) brain-dead rats treated
with saline, or (D) brain-dead rats treated with anti-factor B. (E) Renal macrophage influx was scored in paraffin-embedded sections from (F) sham-operated rats, (G)
brain-dead rats treated with saline, or (H) anti-factor B. Sections were quantified for the number of positive cells in the renal cortex using Aperio Imagescope (objective
50x−200x) and ImageJ Software. All pictures are presented at 200x magnification. Data are shown as median ± IQR. Data were analyzed by Mann Whitney-U-test
and Bonferroni post-hoc test, asterisks above the bars denote significant differences between the brain-dead rats (*p < 0.05, **p < 0.01, and ***p < 0.001). The
dashed line represents the sham-operated rats. #Significant differences between the brain-dead rats vs. sham-operated rats (#p < 0.05, ##p < 0.01, and ###p
< 0.001). Anti-FB, anti-factor B.
levels of IL-1β, IL-18, and P-selectin were lower as well, but
not significantly (Figures 4F,G). Treatment with anti-FB did not
reduce the apoptosis ratio BAX/Bcl-2 in the kidney upon brain
death (Figure 4H). Altogether, the results demonstrate that anti-
FB attenuates the pro-inflammatory response upon brain death.
Treatment With Anti-factor B Reduces the
Influx of Macrophages After 4 h of Brain
Death
To complete the renal inflammatory profile, we determined
the influx of neutrophils and macrophages in the kidney by
immunohistochemistry. After 4 h of brain death, the number of
macrophages (ED-1) and neutrophils HIS(48) in the kidney were
significantly increased in brain-dead rats compared to sham-
operated rats. Next, we investigated the effect of anti-FB on the
influx of leukocytes in the kidney. In brain-dead rats, treatment
with anti-FB led to a significantly lower number of macrophages
in the kidney than in saline-treated rats (Figures 5A–D, p <
0.01). In addition, the absolute number of neutrophils in the
kidney was lower in anti-FB treated rats than in saline-treated rats
(Figures 5E–H). In conclusion, pretreatment with anti-FB seems
to attenuate the influx of leukocytes, especially macrophages, in
the kidney upon brain death.
DISCUSSION
In this study, we investigated whether inhibition of factor B can
attenuate brain death-induced renal injury and inflammation
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in rats. To achieve this, we pretreated rats with a monoclonal
antibody against factor B (anti-FB) and subsequently subjected
the rats to 4 h of brain death. We found that anti-FB preserved
renal function, reduced renal injury and renal inflammation in
brain-dead rats.
First, we studied the effect of anti-FB treatment on systemic
and local complement activation. We observed significantly
lower plasma levels of C3d in anti-FB treated rats than in saline-
treated rats after 4 h of brain death. These results demonstrate
that treatment with anti-FB prevents systemic complement
activation, which might be important because high systemic
complement levels in the donor are associated with acute
rejection of human renal allografts (11). In addition, the present
study demonstrates that pretreatment with anti-FB resulted in
significant less local complement C3d deposition. Of importance,
since previous studies have shown that renal complement C3
synthesis is associated with acute renal transplant rejection and
acute post-ischemic renal failure (3, 10, 21, 22).
Next, we investigated the effect of treatment with anti-FB
on renal function and renal injury after 4 h of brain death.
Treatment with anti-FB preserved renal function in brain-dead
rats. However, serum creatinine levels in anti-FB treated rats were
still higher than creatinine levels measured in sham-operated
rats. We ascribe these small differences in serum creatinine levels
to the hemodynamic changes seen during brain death, which
were not seen in sham-operated rats. Therefore, rats subjected to
brain death received more fluid than sham-operated rats, which
explains the observed differences in plasma creatinine levels
between anti-FB treated rats and sham-operated rats (Table 1).
In addition, we observed an increase in KIM-1 gene expression
levels and KIM-1 deposition in the renal cortex of brain-dead
rats compared to sham-operated rats. Similar observations were
done by Nijboer et al., who showed that KIM-1 is substantially
upregulated in human brain-dead donors (23). The fact that
both KIM-1 gene expression levels and KIM-1 deposition were
reduced in anti-FB treated rats seems to be important since KIM-
1 is known to be an independent predictive marker for renal
function in recipients after renal transplantation (24). Lastly,
since we observed that treatment with anti-FB led to lower
gene expression levels of IL-6, VCAM-1, and MCP-1 after brain
death, it is suggested that anti-FB reduces brain death-induced
renal inflammation. Interestingly, rats treated with anti-FB had
systemic IL-6 levels comparable to sham-operated rats. These
low IL-6 levels could be explained by the fact that Ba and Bb
fragments have a variety of biological activities independent of
the proteolytic activity (25–27).
An important limitation of this study is the fact that anti-
FB was not administered after the confirmation of brain death.
Anti-FB was administered 20min before the start of brain death
induction, which is impossible to realize in clinical practice (28).
Therefore, this study set-up serves as a proof of principle to
investigate the effect of anti-FB on brain death-induced renal
injury in rats. More research is needed to evaluate the effect
of anti-FB during different time points throughout the brain
death period. In the current study, we did not include a group
with anti-FB administration after the induction of brain death.
The optimal time point of intervention would be between 30
and 90min after brain death induction, which leaves only 2–
3 h to evaluate the effect of anti-FB treatment on renal injury
in our brain death model for rats. We consider this too short,
since the maximum effect of anti-FB treatment is apparent
after 4 h (16). Therefore, we consider it as a next step to
investigate the effect of anti-FB treatment after the induction of
brain death in a larger animal model for brain death. Another
limitation of this study is that we only used male rats, to
circumvent sex-related differences in complement levels and
functionality (14, 29).
A study performed by Thurman et al. already demonstrated
the potential of complement factor B inhibition in a mouse
model of renal ischemia/reperfusion. An inhibitory monoclonal
antibody to mouse factor B was used, which significantly
preserved renal function and led to less renal injury (30, 31).
Thus, factor B seems to be a promising target to improve renal
transplant outcome, in both the donor as well as in the recipient.
However, treatment of the donor might be more beneficial than
of the recipient, since the complement system is already activated
in the donor and as has been shown to affect the function of the
renal allograft (11, 32). Taken together, these results create a new
window of opportunity for complement-targeted therapies in the
renal transplantation setting.
However, when treating the donor, it should be considered
that all organs will be treated with the same drug and same
dose of treatment. While our study shows that the quality of the
kidney improves from treatment with anti-FB in the donor, this
is not yet investigated for the other organs. Based on literature,
the heart may also benefit from treatment with anti-FB. Chun
et al. showed that systemic levels of factor B in both mice
and human are positively correlated with myocardial necrosis
after cardiac ischemia/reperfusion injury. In addition, absence
of factor B resulted in significant myocardial protection after
cardiac ischemia/reperfusion (33). Although less is known about
factor B in other organs during transplantation, factor B has been
described to play a pivotal role in multiple pro-inflammatory
disease models, such as retinal injury and arthritis (34, 35).
Altogether, these positive findings resulted in the development
of therapeutic targets against factor B.
Currently, two drugs that can inhibit factor B are tested in
clinical trials. One of them is LPN023, a small molecule that binds
the active site of factor B. LPN023 is currently tested in phase II
dose-ranging study in IgA nephropathy patients [NCT03373461;
(36)]. Recently, Ionis Pharmaceuticals announced to start a phase
II study with their antisense drug against factor B in patients
with age-related macular disease (37). Various agents that target
factor B are currently under development, for example siRNA
against factor B [Alnylam; (38)]. These trials, may soon lead to
the clinical availability of one ormore complement inhibitors that
target factor B.
In conclusion, we show that anti-FB pretreatment in
brain-dead donor rats preserves renal function and protects
against renal injury and renal inflammation. Therefore, anti-FB
treatment might be a potential therapy to reduce brain death-
induced renal injury prior to transplantation.
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